3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18
Gastrointestinal Stromal Tumors
12
Leukemia, Myeloid, Chronic-Phase
9
Leukemia
7
Leukemia, Myeloid, Acute
6
Blast Crisis
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Leukemia, Myeloid, Accelerated Phase
5
Gliosarcoma
5
Glioblastoma
5
Brain Neoplasms
5
Glioma
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Prostatic Neoplasms
3
Philadelphia Chromosome
3
Pancreatic Neoplasms
3
Oligodendroglioma
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Central Nervous System Neoplasms
3
Astrocytoma
3
Primary Myelofibrosis
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
Ipilimumab
10
Nivolumab
9
Interleukin-2
5
Cyclophosphamide
5
pembrolizumab
3
incomplete Freund's adjuvant
3
fludarabine phosphate
3
Radiosurgery
3
Melphalan
3
ADI PEG20
3
sotrastaurin
2
fludarabine
2
Specimen Handling
2
Ranibizumab
2
Magnetic Resonance Spectroscopy
2
MART-1 Antigen
2
CTLA-4 Antigen
2
Biopsy
2
utomilumab
1
tocilizumab
1
siremadlin
1
sargramostim
1
ruxolitinib
1
relatlimab
1
pentetreotide
1
obinutuzumab
1
montanide ISA 51
1
lifileucel
1
gp100 Melanoma Antigen
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Uveal Melanoma
×
Imatinib Mesylate
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled